Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Boston Scientific reports outcomes from trial of LAAC device
The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
Boston Scientific’s WATCHMAN FLX: Poised for Growth with New Trial Results and Reimbursement Code
Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black
Boston Scientific Watchman FLX demonstrates superiority to anticoagulants in study
Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.
Boston Sci stock climbs 5% on positive Watchman FLX data
Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.
Buy Rating on Boston Scientific: WATCHMAN Product’s Expanding Market Potential and Revenue Growth
In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report),
Boston Scientific’s Watchman could be new option for patients post ablation: study
The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent cardiac ablation for AFib.
FierceBiotech
22h
AHA 2024: Boston Scientific, Abbott tout long-term heart occluder data
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
Zacks.com on MSN
1d
Boston Scientific Stock Set to Gain From Completion of Axonics Deal
Boston Scientific Corporation BSX recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat ...
Orange County Business Journal
1d
Boston Scientific Completes $3.7B Acquisition of Axonics
Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...
Benzinga.com
2d
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...
health.economictimes.indiatimes
1d
Boston Scientific launches multi-functional imaging system AVVIGO
AVVIGO is an intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system designed to provide high-quality IVUS ...
Pharmabiz
1d
Boston Scientific WATCHMAN FLX LAAC device demonstrates superior bleeding risk reduction to OAC following a cardiac ablation in OPTION clinical trial
Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...
MassDevice
4d
Boston Scientific finalizes $3.7B acquisition of Axonics
Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).
1d
Boston Scientific (BSX) Gets a Buy from Truist Financial
In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Boston Scientific (BSX – Research Report). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Trade
Axonics
WATCHMAN FLX
Left atrial appendage occlusion
Anticoagulant
Feedback